



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR          | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|-------------------------------|---------------------|------------------|
| 09/749,025      | 12/27/2000  | Petrus Johannes Maria Nuijten | 99511 US            | 6121             |

7590

08/12/2004

Bretton L Crockett

230 South 500 East

Suite 300

Salt Lake City, UT 84110

EXAMINER

FORD, VANESSA L

ART UNIT

PAPER NUMBER

1645

DATE MAILED: 08/12/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

09/749,025

Applicant(s)

NUIJTEN ET AL

Examiner

Vanessa L. Ford

Art Unit

1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

## Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☒ Responsive to communication(s) filed on 20 May 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 7-11 and 19-29 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 7-11, 19, 20 and 22-29 is/are rejected.
- 7) ☒ Claim(s) 21 is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 03 January 2002 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

## Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some \* c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

## Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_
- 5) ☐ Notice of Informal Patent Application (PTO-)
- 6) ☐ Other: \_\_\_\_\_

### **DETAILED ACTION**

1. Applicant's amendment and response filed May 20, 2004 is acknowledged. Claims 1-6 and 12-18 have been cancelled. Claims 7-11, 19 and 21 have been amended. Claims 22-29 have been added.

### ***Objection/Rejection Withdrawn***

2. In view of Applicant amendment and response the following rejections have been withdrawn:
  - a) objection of specification, page 10, paragraph 5.
  - b) objection of claim 20, page 9, paragraph 4.
  - c) rejection of claim 21 under 35 U.S.C. 112, second paragraph, page 10, paragraph 5.

### ***Rejection Maintained***

3. The rejection under 35 U.S.C. 112, first paragraph is maintained for claims 7-11, 19-20 and newly submitted claims 22-29 for the reasons set forth on pages 2-9, paragraph 2 of the previous Office Action.

The rejection was on the grounds that the claims are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a vaccine composition for the protection against Salmonellosis comprising an immunologically effective amount of a *Salmonella typhimurium* STMP mutated bacterium and a pharmaceutical acceptable carrier, wherein the mutated bacterium lacking flagellin does not reasonably provide enablement for a vaccine composition for the protection against Salmonellosis comprising an immunologically effective amount of any *Salmonella* mutated bacterium wherein the mutated bacterium lacking flagellin and wherein the mutated bacterium is attenuated. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Art Unit: 1645

The specification has not provided enablement for: A) a vaccine comprising any mutated *Salmonella* bacterium from the group consisting of *Salmonella* species *typhimurium*, *enteritidis*, *cholerasuis*, *dublin*, *abortus-ovi*, *abortus-equi*, *derby*, *habar*, *heidelberg*, *agona* and *arizonae* wherein said mutated bacterium lacking flagellin and wherein the vaccine is protective, B) a vaccine comprising any mutated *Salmonella* bacterium from the group consisting of *Salmonella* species *typhimurium*, *enteritidis*, *cholerasuis*, *dublin*, *abortus-ovi*, *abortus-equi*, *derby*, *habar*, *heidelberg*, *agona* and *arizonae*, wherein said mutated bacterium lacking flagellin and wherein the mutated bacterium is attenuated.

The claims are drawn to a vaccine composition. The term "vaccine" encompasses the ability of the specific antigen to induce protective immunity to *Salmonella* infection or disease induction. The specification teaches that current *Salmonella* vaccines are efficacious however they share a serious disadvantage because they generally induce an antibody population that equals that of an infection with wild-type bacteria because they possess the same antigenic load as the wild-type bacterium. The specification teaches that analysis of antibodies in the serum of *Salmonella*-positive animal does not reveal why the animal is positive, this can be due to vaccination or caused by infection with a virulent strain (page 4). The specification teaches that it would be advantages to have a so-called marker-vaccine comprising an antibody panel that differs from that of the wild-type infection and therefore the host would not make antibodies against the marker (i.e. protein) after vaccination (page 4). The specification teaches that the bacteria is no longer capable of inducing antibodies against at least one antigenic determinant of flagellin or flagella and are considered to be bacteria that do not comprise flagellin or flagella but still possesses all the antigenic determinants (page 6). Example 3 (Experiment 1) of the specification teaches that broilers were inoculated orally, subcutaneously and intramuscularly with a vaccine comprising a wild-type flagellated (fla+) *S. typhimurium* (STMP), a vaccine comprising non-flagellated (fla-) *S. typhimurium* (STM2000) or a vaccine comprising wild-type *S. typhimurium*. The results of this experiment show that 8 out of 10 animals given the wild-type vaccine died and the surviving two had swollen livers with necrotic foci, swollen spleen and pericardial edema. One of the STMP inoculated chickens had a slight swollen liver and one of the STM2000 inoculated chickens had a slightly swollen spleen. No further abnormalities were note in the STMP or the STM2000 inoculated groups. Example 3, (Experiment 2) of the specification teaches a vaccine comprising a wild-type flagellated (fla+) *S. typhimurium* (STMP) and a vaccine comprising non-flagellated (fla-) *S. typhimurium* (STM2000) both administered orally into broilers followed by challenge infection with wild-type *S. typhimurium*. The results of the experiment show that a larger proportion of the chickens in the STMP inoculated group was culture positive after direct plating indicates that this strain colonizes the intestinal tract in higher numbers than the STM2000 strain. Example 4 of the specification teaches that pigs were inoculated orally with STMP or STM2000 followed by an oral challenge infection with wild-type *S. typhimurium*. The results of this experiment in Table 5 show that both vaccine strains were able to reduce fecal shedding of the challenge strain significantly.

Art Unit: 1645

The teachings of the prior art regarding *Salmonella* nonflagellated mutants are cited below:

Lockman et al (*Infection and Immunity*, January 1990, p. 137-143) teach nonflagellated mutants of *Salmonella typhimurium* (see the Title). Lockman et al teach that flagella enable bacterial cells to move chemotactically in response to stimuli and there is evidence that these organelles function in the attachment of certain bacteria to solid surfaces (page 141, 1<sup>st</sup> column). Lockman et al teach that flagella (H antigen) on the surface of *Salmonella typhimurium* have been characterized as virulence factors that help the bacteria move towards and adhere to the host cells (page 137, 1<sup>st</sup> column). Lockman et al teach that passive immunization of mice with anti-H antiserum did not protect the animals from a lethal challenge with virulent organisms, although the antiserum inhibited bacterial adherence to intestinal epithelium *in vitro* (page 137, 1<sup>st</sup> column). Lockman et al teach that nonflagellated strains colonized the intestinal tracts of orally vaccinated mice as well as isogenic flagellated strains yet did not confer equal protection from subsequent lethal challenge by motile *S. typhimurium* (page 137, 2<sup>nd</sup> column). Lockman et al teach that flagella were necessary for *S. typhimurium* to invade and cause severe disease and the nonflagellated strains were equally proficient at colonization of the murine intestinal tract, but these mutants were deficient in invasion of the reticuloendothelial system (2<sup>nd</sup> column, page 141). Hackett et al (*The Journal of Infectious Diseases*, Vol. 157, January 1988) teach protective and nonprotective strains of *Salmonella*. Hackett et al teach that when mice were fed strains of *Salmonella* a limited infection in the Peyer's patches was established and generated resistance to subsequent challenge with virulent *S. typhimurium* C5 and the these five strains of *Salmonella* are termed "protective" because they did not give rise to bacteremia or colonization in the liver or spleen (1<sup>st</sup> column, page 80). Hackett et al teach that also teach eight strains of *Salmonella* and one strain from *E. coli* expressing O-antigens 1,4,5 and 12 of *S. typhimurium* administered to mice orally that fail to induce resistance to the virulent *S. typhimurium* C5 challenge, these strains are termed "nonprotective" (page 80 in particular, Table 1). Hackett et al teach that *S. typhimurium* C5 and the five protective strains expressed one to two prominent cell envelope polypeptides of 50-55 kDa which were not expressed by the nonprotective strains with the exception of *S. derby*. Hackett et al teach that these polypeptides were loosely associated with the cell envelope and there molecular mass values of about 50 to 55 kDa suggesting that they might be composed of flagellin. Hackett et al confirmed that six of the "protective" strains in which polypeptides were detected contained flagellin either (the H-1i antigen or the H-2 1 antigen) (page 80 and figures 1B and C). Hackett et al teach that *S. typhimurium* C5 and all five of protective strains examined expressed high levels of flagella whereas only one of the eight nonprotective did so (page 81). Hackett et al suggests a correlation between the expression of high levels of flagellin by a *Salmonella* strain, its ability to colonize mice when given orally and its ability to protect against subsequent oral *S. typhimurium* C5 challenge (page 81). Hackett et al determined that there is a correlation between protection and colonization by administering orally to mice flagella-positive (fla+) and flagella-negative (fla-) strains of *Salmonella*. Hackett et al teach that the fla- colonized the Peyer's patch as well as the fla+ strains and when

Art Unit: 1645

give orally no strain colonized the spleens of infected mice (1<sup>st</sup> column, page 82). Hackett et al teach that there is a correlation between flagella expression and protective efficacy because mice immunized with fla+ strains showed lower numbers of challenge bacteria in the spleen than did mice immunized with the fla- strains, a result agreeing with the greater protective effects of immunization with the fla+ strains. Hackett et al teach that the levels of challenge strain in the spleens of the immunized mice were similar to three days postinfection, but mice immunized with fla+ strains eliminated the challenge whereas the mice immunized with fla- strains did not (pages 81-82). Hackett et al teach that it is uncertain whether the relative inefficacy of the fla- vaccines results from their inability to elicit immunity to flagella or from their inability (compared with fla+ strains) to induce immune responses to a wider range of bacterial antigens (2<sup>nd</sup> column, page 83). Hackett et al teach that flagella promote the intracellular survival of *Salmonella* after ingestion by macrophages and therefore fla+ and fla- bacteria are perhaps "processed" differently by these cells because macrophages can function as antigen presenting cells and this might lead to qualitative and quantitative differences in immune response (2<sup>nd</sup> column, page 83). Wahdan et al (*Bull World Health Organization*, vol. 52, 1975) teach a nonmotile mutant of *Salmonella typhi* Ty2 which produces high levels of Vi and O titers but is devoid of the flagellar antigen (does not induce formation of H antibody) (page 69). Wahdan et al teach that the nonmotile vaccine was produced with strain TNM1 (page 69). Wahdan et al teach that the TNM1 vaccine is identical to other *S. typhi* whole cell vaccines prepared with Ty2 except that it is devoid of the H antigen and therefore does not interfere with the Widal test for H antibody (page 71). Wahdan et al teach that the TNM1 vaccine did not provide protection. Wahdan et al teach that there is a correlation between the H antibody and protection and suggests that it seems more probable that a property other than the synthesis of flagellar antigen determines immunogenicity and it is absent from the TNM1 non-motile mutant (page 72).

The vaccine composition "is in live attenuated form". The specification teaches that the claimed vaccine compositions can be in a live attenuated form or inactivated (page 11). The specification teaches that the development of live attenuated vaccines in general is difficult and time consuming. The specification teaches that fine-tuning of the degree of attenuation is complex because high virulence causes disease and low virulence induces insufficient protection (page 11). The specification teaches that removal of the flagellin gene does not significantly change the level of attenuation (page 11). Lockman et al (*Infection and Immunity*, January 1990, p. 137-143) teach that the role of the flaF25 mutation in the attenuation of *S. typhimurium* is unclear. The flaF25 mutation was correlated with flagellar biosynthesis and was originally described as a deletion of unknown size within the flaF gene cluster but was subsequently report as a deletion of genes flaFI through flaFV. The flaF25 mutation had been reported to involve not only some of the genes encoding the biosynthesis of flagella but extended into to a previously undescribed virulence gene(s) (2<sup>nd</sup> column, page 137).

The prior art has taught that flagella (H antigen) enable bacterial cells to move chemotactically in response to stimuli and there is evidence that these organelles function in the attachment of certain bacteria to solid surfaces. The prior art has taught

Art Unit: 1645

flagella have been characterized as virulence factors. The prior art has taught that fla+ strains express one to two proteins of about 50 to 55 kDa which correspond to the H-1i antigen and the H-2 1 antigen (i.e. flagellin) with the exception of *S. derby*. There is a correlation between high level of flagella, colonization and protection regarding protective *Salmonella* strains. The prior art teaches that although fla+ and fla- strains equally colonize the Peyers patch, the fla+ strains eliminated challenge bacteria whereas the fla- strains did not. The prior art teaches that live oral *Salmonella* vaccines comprising fla+ strains have been found to be superior against *S. typhimurium* C5 infection in mice. The prior art teaches that fla+ strains may be superior vaccines because macrophages may process bacteria cells that contain flagella differently than those that do not since the prior art has taught that macrophages can function as antigen presenting cells. The prior art has taught that there is a correlation between protection and the H antigen since a nonmotile mutant (lacking the H antigen) of *Salmonella typhi* did not protect patients against typhoid fever. The prior also teaches that a property other than the synthesis of flagellar antigen determines immunogenicity and it is absent from the TNM1 non-motile mutant. The prior art that the role of attenuation to produce *Salmonella* nonflagelated mutants is unclear.

Factors to be considered in determining whether undue experimentation is required are set forth in *In re Wands* 8 USPQ2d 1400. They include (1) the quantity of experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art and (8) the breadth of the claims.

In view of the teachings of the specification (or the lack thereof) and the teachings of the prior art there is lack of enablement for the a vaccine comprising any mutated *Salmonella* bacterium from the group consisting of *Salmonella* species *typhimurium*, *enteritidis*, *cholerasuis*, *dublin*, *abortus-ovi*, *abortus-equi*, *derby*, *habar*, *heidelberg*, *agona*, *arizonae*, *typhi* or *paratyphi A and B*, wherein said mutated bacterium lacking flagellin and the said vaccine composition is protective. The specification has shown that the vaccines comprising mutated bacterium lacking flagellin from *S. typhimurium* STMP are protective. It is determine that there are limited working examples commensurate in scope with the instant claims and there is limited guidance provided in the specification as to how to make and use vaccine compositions that comprise a mutated from any *Salmonella* bacterium (other than STM2000) lacking flagellin that are protective against Salmonellosis. The skilled artisan is forced into undue experimentation to practice (make and use) the invention as is broadly claimed because the prior art has taught that many strains of fla- are not protective, do not confer protection from subsequent challenge by motile *Salmonella* bacteria and that mutations such as the flaF25 mutation in the attenuation of *Salmonella* bacterium is unclear.

Applicant urges that claims 7 and 19 were amended to remove the language "for the protection of animals against Salmonellosis" from the description of the respective

Art Unit: 1645

vaccines and the enablement of these claims as directed to marker vaccines was discussed. Applicant urges that claims 7 and 19 are directed to a marker vaccine that allows exposure of an animal to a wild-type strain to be detected by antibody testing and the specification enables the manufacture and use of such vaccines with multiple *Salmonella* strains. Applicant urges that Example 3 of the specification demonstrates that two different vaccine strains comprising STMP and STM2000 were able to reduce fecal shedding of a challenged strain significantly and that the STMP and STM200 inoculated chickens survived compared to an 80% death rate for those inoculated with a wild-type vaccine. Applicant urges that Example 4, at pages 22-23 of the specification teaches that live attenuated flagella-less *S. typhimurium* vaccine according to the invention give excellent results in pigs. Applicant urges that support is provided in Example 2, of the specification which shows that vaccines comprising flagellated and non-flagellated *Salmonellas* specifically *S. enteritidis* fla+ and *S. enteritidis* fla-. Applicant urges that Example 2 discloses that *S. enteritidis* fla- vaccines also provides a clearly recognizable marker. Applicant urges that the Office refers to the Wahdan et al, Lockman et al and Hackett et al to support the position that the claimed invention is not enabled for the use of *Salmonella* vaccines. Applicant urges that Lockman et al discusses the Hackett et al reference and discloses that the Hackett's flagella-less mutant has a mutation not only involves some of the genes encoding the biosynthesis of flagella but extended into previous undescribed virulence genes. Applicant urges that Wahdan et al relates "to *S. typhi* and *S. paratyphi* A/B which are not claimed in the instant claims" discloses that "it seems more probable that a property other than the



synthesis of the flagellar antigen determines immunogenicity and is absent from this non-motile motif. Applicant urges that Examples 3 and 4 of the instant specification show live attenuated flagella-less *S. typhimurium* vaccines, in contrast to Hackett et al, which teach that many fla-*Salmonella* strains are not protective. Applicant urges that are enabled.

Applicant's arguments filed May 20, 2004 have been fully considered but they are not persuasive. It is the Examiner's position that the instant specification only enables the use of *Salmonella typhimurium* STMP mutated bacterium in a vaccine composition for the protection against Salmonellosis. The Examiner disagrees with Applicant's assertion that "claims 7 and 19 are directed to a marker vaccine that allows exposure of an animal to a wild-type strain to be detected by antibody testing and the specification enables manufacture and use of such vaccines with multiple *Salmonella* strains". Claims 7 and 19 are directed to a vaccine comprising an immunologically effective amount of a mutated bacterium and pharmaceutically acceptable carrier, said mutated bacterium being selected from the group consisting of the *Salmonella* species *typhimurium*, *enteritidis*, *choleraesuis*, *dublin*, *abortus-ovi*, *abortus-equi*, *derby*, *hadar*, *heidelberg*, *agona* and *arizonae* that in its wild-type form carries flagella said mutated bacterium lacking flagellin. While Wahdan et al do not teach one of the claimed species of *Salmonella* used in a vaccine composition, Wahdan et al was cited to teach that all *Salmonella* strains are which are devoid of the flagellar antigen are not protective. In regards to Lockman et al, Applicant agrees with the statement that "rendering a live attenuated fla<sup>positive</sup> strain into a fla<sup>minus</sup> strains does not change the virulence of the

Art Unit: 1645

strain". It should be noted that Lockman et al demonstrates that nonflagellated strains of *S. typhimurium* did not confer equal protection from subsequent lethal challenge by motile *S. typhimurium*. In regards to Hackett et al, Applicant states that "Hackett et al is wrong in their teaching that fla- strains are not protective". Hackett et al teach that there is a correlation between flagella expression and protective efficacy in mice immunized with fla+ and fla- strains. Hackett et al demonstrates that fla+ strains of *Salmonella* eliminated *Salmonella typhimurium* C5 challenge while fla- strains of *Salmonella* did not. It should be remembered that Hackett et al teach a *S. typhimurium* M206 bacterium that did not synthesize flagella (i.e. mutated bacterium lacking flagellin)(page 81) and is not protective against *Salmonella typhimurium* C5 challenge in mice (page 80, table 1). It should be noted the claims are not so limited to *Salmonella* bacterium that have mutation/mutations is in only the genes associated with synthesis of the flagella. The claims merely recite "mutated bacterium ... that in its wild-type form carries flagella, said mutated bacterium lacking flagellin". Thus, the claims do not define the actual mutation/mutations that are made in the *Salmonella* bacterium. One of skill in the art would not conclude that all strains of *Salmonella* encompassed by the claimed invention are protective based on the teachings of the prior art. Therefore, the specification is only enabled for vaccine compositions for the protection against Salmonellosis comprising an immunologically effective amount of a *Salmonella typhimurium* STMP mutated bacterium and a pharmaceutical acceptable carrier.

### **New Grounds of Rejection**

#### **Claim Objection**

4. Claim 21 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

#### ***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

5. Claims 7-8, 20, 22-25 and 29 are rejected under 35 U.S.C. 102(b) as anticipated by Joys et al (*Journal of General Microbiology*. 1965, 41, 47-55).

Claims 7-8, 20, 22-25 and 29 are drawn to a vaccine comprising an immunologically effective amount of a mutated bacterium and a pharmaceutically acceptable carrier, said mutant bacterium being selected from the group consisting of *Salmonella* species *typhimurium*, *enteritidis*, *cholerasuis*, *dublin*, *abortus-ovi*, *abortus-equi*, *derby*, *habar*, *heidelberg*, *agona* and *arizonae*.

Joys et al teach compositions comprising fla- *Salmonella typhimurium* bacterium in broth culture (page 48-49). Broth culture is a pharmaceutically acceptable carrier because the instant specification teaches that "such a carrier may be as simple as water, but e.g. also comprise culture fluid in which the bacteria were cultured (page 12).

Art Unit: 1645

Claim limitations such as "marker vaccine" and "vaccine" are being viewed as limitations of intended use. It should be remembered that a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim.

Since the Office does not have the facilities for examining and comparing applicant's vaccine with the vaccine of the prior art, the burden is on the applicant to show a novel or unobvious difference between the claimed product and the product of the prior art (i.e., that the vaccine of the prior art does not possess the same material structural and functional characteristics of the claimed vaccine). See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

### ***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. Claims 7-8, 11, 20, 22-25 and 28-29 are rejected under 35 U.S.C. 103(a) as unpatentable over Joys et al (*Journal of General Microbiology*. 1965, 41, 47-55) in view of Hansen et al (*U.S. Patent 5,665,363 published September 9, 1997*).

Art Unit: 1645

Claims 7-8, 20, 22-25 and 29 are drawn to a vaccine comprising an immunologically effective amount of a mutated bacterium and a pharmaceutically acceptable carrier, said mutant bacterium being selected from the group consisting of *Salmonella* species *typhimurium*, *enteritidis*, *cholerasuis*, *dublin*, *abortus-ovi*, *abortus-equi*, *derby*, *habar*, *heidelberg*, *agona* and *arizonae*, wherein the marker vaccine is freeze-dried or spray-dried.

Joys et al teach compositions comprising fla- *Salmonella typhimurium* bacterium in broth culture (page 48-49). Broth culture is a pharmaceutically acceptable carrier because the instant specification teaches that "such a carrier may be as simple as water, but e.g. also comprise culture fluid in which the bacteria were cultured (page 12). Claim limitations such as "marker vaccine" and "vaccine" are being viewed as limitations of intended use. It should be remembered that a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim.

Joys et al do not teach compositions that are freeze-dried or spray-dried.

Hansen et al teach that pharmaceutical compositions comprising live or killed microorganisms can be freeze-dried or spray-dried (column 4, lines 17-22).

It would have been *prima facie* obvious to one having ordinary skill in the art at the time the invention was made to freeze-dry the compositions comprising fla- *Salmonella typhimurium* bacterium as taught by Joys et al because Hansen et al teach

Art Unit: 1645

that pharmaceutical compositions comprising live or killed microorganisms can be freeze-dried or spray-dried.

### **Conclusion**

7. Any inquiry of the general nature or relating to the status of this general application should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Papers relating to this application may be submitted to Technology Center 1600, Group 1640 by facsimile transmission. The faxing of such papers must conform with the notice published in the Office Gazette, 1096 OG 30 (November 15, 1989). Should applicant wish to FAX a response, the current FAX number for the Group 1600 is (703) 872-9306.

Any inquiry concerning this communication from the examiner should be directed to Vanessa L. Ford, whose telephone number is (571) 272-0857. The examiner can normally be reached on Monday – Friday from 9:00 AM to 6:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith, can be reached at (571) 272-0864.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov/>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

  
Vanessa L. Ford  
Biotechnology Patent Examiner  
August 1, 2004

  
PATRICIA A. DUFFY  
PRIMARY EXAMINER